Hermetica Superfood Encyclopedia
The Short Answer
Iboga root bark contains ibogaine (1.93% w/w) as its primary alkaloid, which disrupts addiction pathways through non-competitive inhibition of serotonin and dopamine reuptake while modulating NMDA, opioid, and nicotinic receptors. This multitarget mechanism induces GDNF/BDNF neurotrophic signaling that promotes neuroplasticity and reduces drug-seeking behavior in preclinical models.
CategoryRoot & Tuber
GroupRoot/Rhizome
Evidence LevelModerate
Primary KeywordIboga Root supplement
Synergy Pairings4
Iboga Root — botanical close-up
Health Benefits
**Supports addiction recovery,**
particularly for opioid and stimulant dependence, by disrupting craving pathways.
**Enhances neuroplasticity, potentially**
aiding in brain repair and cognitive flexibility.
**Modulates mood and**
facilitates trauma processing through its psychoactive effects.
**Stimulates deep introspection**: and promotes self-awareness
**Improves cognitive clarity**: and focus in controlled settings
Origin & History
Natural habitat
Iboga Root (Tabernanthe iboga) is derived from a rainforest shrub native to Central West Africa, primarily Gabon, Cameroon, and the Republic of Congo. Revered for its psychoactive properties, this root is a cornerstone of traditional Bwiti spiritual practices and is now studied for its therapeutic potential.
“Iboga Root is sacred in the Bwiti tradition of Central West Africa, where it is used in rites of passage, healing, and ancestral communication. Revered as a powerful plant teacher, it is believed to reveal suppressed memories and spiritual insights, with ceremonies involving deep preparation and integration guided by trained initiates.”Traditional Medicine
Scientific Research
Extensive scientific studies, including clinical trials and pharmacological research, investigate Ibogaine's efficacy in addiction therapy, particularly for opioid and stimulant dependence. Research published in NCBI and ScienceDirect explores its neuroplastic effects, mechanisms in trauma processing, and pharmacokinetic profile, alongside safety considerations.
Preparation & Dosage
Traditional preparation
Common forms
Whole root bark, powdered extract (ibogaine HCl).
Traditional Use
Ceremonially consumed in specific doses by Bwiti spiritual practitioners.
Clinical Use
15–25 mg/kg of ibogaine HCl)
Administered under strict medical supervision for addiction therapy (e.g., .
Microdosing
1–5 mg of ibogaine in supervised settings
<.
Contraindications
Contraindicated with SSRIs, opioids, or QT-prolonging medications due to potential cardiac risks.
Nutritional Profile
- Indole Alkaloids: Primarily Ibogaine, Noribogaine, and Tabernanthine.
- Neuroactive Compounds: Modulate dopaminergic, serotonergic, and opioid receptor systems.
- Neurotrophic Factors: Promotes Brain-Derived Neurotrophic Factor (BDNF) expression.
- Synaptic Modulators: Supports synaptic reorganization and neuroplasticity.
How It Works
Mechanism of Action
Ibogaine non-competitively inhibits serotonin (SERT) and dopamine (DAT) reuptake transporters while stabilizing their inward-facing conformation. It acts as an NMDA receptor antagonist, binds to sigma-1/2 receptors, modulates opioid and nicotinic receptors, and demonstrates 5-HT2A agonism. This multitarget activity triggers GDNF/BDNF neurotrophic factor release, promoting dendritic arbor complexity and neural recalibration in addiction circuits.
Clinical Evidence
Current evidence is primarily limited to preclinical rodent studies demonstrating ibogaine's ability to reduce self-administration of opiates, amphetamines, alcohol, and nicotine. Extensive pharmacological research published in NCBI and ScienceDirect investigates ibogaine's mechanisms and safety profile, but specific human clinical trial data with quantified success rates or abstinence durations are not available in current literature. Research focuses on understanding neuroplastic effects and pharmacokinetic properties rather than controlled efficacy outcomes. Evidence strength remains at the preclinical level despite widespread interest in addiction therapy applications.
Safety & Interactions
Iboga root presents significant cardiotoxicity risks including QT prolongation and potentially fatal arrhythmias, alongside general toxicity concerns demonstrated in preclinical models. CYP2D6 inhibitors like paroxetine can double ibogaine and noribogaine exposure, dramatically increasing toxicity risk due to the compound's lipophilic nature and tissue sequestration. Contraindications include cardiac conditions, hepatic impairment, and concurrent use of medications affecting CYP2D6 metabolism. The complex and partly unknown mechanisms limit predictability of interactions, making medical supervision essential.
Synergy Stack
Hermetica Formulation Heuristic
Adaptogenic base
Cognition & Focus | Mood & Stress
Also Known As
Tabernanthe ibogaibogaine root barkBwiti rootvoacangine sourceAfrican peach root
Frequently Asked Questions
What is the primary active compound in iboga root?
Ibogaine is the predominant alkaloid at 1.93% w/w concentration, comprising 24.6% of total chromatographic area. Minor alkaloids include noribogaine, coronaridine, tabernantine, and dihydrocoronaridine, plus phenolic compounds like caffeoylquinic acids.
How does iboga root work for addiction treatment?
Ibogaine disrupts addiction pathways through multitarget mechanisms including serotonin and dopamine reuptake inhibition, NMDA receptor antagonism, and opioid receptor modulation. It induces GDNF/BDNF neurotrophic signaling that promotes neuroplasticity and reduces drug-seeking behavior in preclinical studies.
What are the main safety risks of iboga root?
Primary concerns include cardiotoxicity with QT prolongation leading to potentially fatal arrhythmias, demonstrated in preclinical toxicity studies. CYP2D6 drug interactions can double exposure levels, and the lipophilic nature causes tissue sequestration with unpredictable effects.
Is there clinical evidence for iboga root effectiveness?
Current evidence is limited to preclinical rodent studies showing reduced self-administration of various substances including opiates, amphetamines, and alcohol. Human clinical trial data with specific success rates or quantified outcomes are not available in published literature.
What drugs interact with iboga root?
CYP2D6 inhibitors like paroxetine significantly increase ibogaine and noribogaine blood levels, doubling exposure and toxicity risk. Liver impairment exacerbates interactions due to dependence on CYP2D6 metabolism, making polypharmacy particularly dangerous with this compound.
What is the difference between iboga root extract and iboga root powder in terms of potency and use?
Iboga root extract is concentrated and standardized, making dosing more predictable and requiring smaller quantities, while powder is the whole plant material with variable alkaloid concentrations. Extracts are typically preferred for therapeutic addiction treatment due to precise dosing, whereas powder is sometimes used for general cognitive and introspective purposes. The extraction process removes plant matter, potentially reducing gastrointestinal side effects associated with taking larger volumes of powder.
Who is the ideal candidate for iboga root use, and who should absolutely avoid it?
Iboga root is primarily intended for adults with opioid or stimulant addiction who have access to medical supervision, as it works best in structured therapeutic settings with trained facilitators. People with cardiac conditions, uncontrolled hypertension, liver disease, or a personal/family history of sudden cardiac death should avoid iboga entirely due to its cardiovascular effects. Pregnant women, nursing mothers, and individuals with severe mental health conditions (such as active psychosis) should not use iboga root due to risks to fetal development and potential psychiatric destabilization.
How long does an iboga root experience typically last, and what is the typical timeline for effects?
A single iboga root session typically lasts 24–48 hours from initial ingestion, with peak psychoactive effects occurring within 4–8 hours of administration. The acute physical effects (elevated heart rate, nausea) usually subside within 12–24 hours, though psychological insights and mood changes may persist for days or weeks afterward. Recovery and integration periods of several days are typically recommended before resuming normal activities, as users often experience fatigue and introspective processing during this time.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w iboga-root curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
